Atavistik Bio’s $120 million Series B financing bolsters its push to advance first-in-class, allosteric small-molecule therapies for HHT and MPNs, leveraging its AMPS platform to selectively target ...
BioMarin Pharmaceuticals entered into a definitive agreement to acquire Amicus Therapeutics to expand its position in rare diseases, increase revenue growth, and strengthen the co ...
In today’s Pharmaceutical Executive Daily, Pfizer discloses its 2026 revenue expectations, a bipartisan group of House ...
Novo Nordisk’s NDA filing for CagriSema positions the first fixed-dose amylin–GLP-1 combination as a potential ...
Harbour BioMed announced it has entered a multi-year, global strategic collaboration and license agreement with Bristol Myers ...
Lilly’s Attain-Maintain Phase III results show that the oral GLP-1 orforglipron can effectively preserve weight loss after injectable therapy, positioning it as a potential long-term maintenance ...
ADEL-Y01, a monoclonal antibody targeting tau protein, is in Phase I trials for Alzheimer's disease, developed by ADEL and ...
Four GOP members of the House of Representatives joined with House Democrats to force a vote on extending tax credits that ...
The Biosecure Act aims to prevent federal funding to Chinese biotech companies labeled "of concern" by the Office of Management and Budget or the Department of Defense. A political shift in the House ...
In today’s Pharmaceutical Executive Daily, the FDA approves a new LDL-lowering therapy, Sanofi announces two strategic deals ...
Lunit’s new collaboration with Daiichi Sankyo integrates AI-driven digital pathology tools into oncology translational ...
The imminent end of the rebate era means human resources (HR) benefits decision-makers and pharmacy consultants are about to see a paradigm shift. They will need to act quickly to adjust benefits ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results